U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07714382) titled 'Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer' on July 15.
Brief Summary: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with a poor prognosis. Although neoadjuvant therapy improves outcomes in patients who achieve a pathological complete response, the presence of residual disease after treatment remains associated with an increased risk of recurrence and death. This retrospective cohort study aims to evaluate the survival outcomes of patients with residual disease following neoadjuvant therapy for TNBC and to assess the association between clinicopathological chara...